PEDIATRIC CHTN--AIDS CANCER RESEARCH

描述：(申请人提供) 分子生物学与病理学的结合正在迅速成为 儿科协作人在儿科癌症诊断中的实践 组织网络(CHTN)，我们的工作假设是集中跟踪， 儿科组织标本的采购/制备和分发 生物医学和分子生物学研究。儿科癌症仍然是 儿童疾病死亡的头号原因及其研究 遗传机制可以作为成人癌症研究的模型。我们的 具体目标有四个：1)扩大儿科肿瘤采购工作 与新合并的儿童？S肿瘤科小组(C.O.G.)，2)加强 通过新技术处理组织以促进分子研究， 3)启动新的知情同意程序，促进与 临床结果，以及4)扩大稀有标本的网络(白血病， 青少年癌症)通过CHTN机制增加调查人员 进入。为了实现这些目标，儿科CHTN最近与 C.O.G.应该会为94%的儿童癌症提供新的途径 北美-多达三分之二的患者加入了临床方案。 儿科CHTN将为儿科药材加工提供新技术 癌症组织--试剂盒中的“RNA后期”溶液、核酸提取、激光 捕获显微镜和组织微阵列以促进分子生物学 学习。儿科CHTN和C.O.G.也将合作放置通知 同意手术或其他程序上的同意书--以便“预先” 知情同意可能会改善患者进入临床程序(Goal&GT；90 百分比)与临床随访的联系。最后，儿科CHTN 而C.O.G.将合作改善研究人员通过CHTN接触癌症的机会 对于分子研究来说是很难获得的(青少年、癌症、 白血病)。这些目标的实现应有助于儿科CHTN 在新千年进一步促进儿科癌症研究。

DESCRIPTION: (Provided by Applicant) Molecular biology combined with pathology is fast becoming the standard of practice in pediatric cancer diagnosis within the Pediatric Cooperative Human Tissue Network (CHTN), our working hypothesis is the centralized tracking, procurement/preparation and dispersal of pediatric tissue specimens facilitate biomedical and molecular biologic research. Pediatric cancer remains the number one cause of death due to disease in children, and studies of its genetic mechanisms may serve as a model for studies of adult cancers. Our SPECIFIC AIMS are fourfold: 1) to expand pediatric tumor procurement working with the newly-unified Children?s Oncology Group (C.O.G.), 2) to enhance processing of tissues via new technologies to facilitate molecular research, 3) to initiate new informed consent procedures facilitating linkage to clinical outcomes, and 4) to expand networking of rare specimens (leukemias, adolescent cancers) through the CHTN mechanisms to increase investigator access. To achieve these aims, the Pediatric CHTN has newly partnered with the C.O.G. which should provide new access to 94 percent of pediatric cancers in North America - with up to two-thirds of patients joining clinical protocols. The Pediatric CHTN will offer new technologies for processing of pediatric cancer tissues - "RNA Later" solution in kits, nucleic acid extractions, Laser Capture Microscopy, and tissue microarrays to facilitate molecular biologic studies. The Pediatric CHTN and C.O.G. will also partner to place informed consents on surgical or other procedural consent forms -so that "up-front" informed consent may improve patient entry onto clinical protocols (goal >90 percent) with its linkage to clinical follow-up. Finally, the Pediatric CHTN and C.O.G. will partner to improve investigator access via the CHTN to cancers which are rare to obtain for molecular studies (adolescent, cancers, leukemias). Achievement of these aims should help the Pediatric CHTN to further facilitate pediatric cancer research in the new millennium.